What Strepfen Treats: Main Uses and Benefits

The core therapeutic purpose of Strepfen is to provide supportive relief during acute episodes of oropharyngeal distress. The lozenge is commonly used in situations involving acute sore throat symptoms.

This therapy is relevant for easing symptoms related to physical discomfort in the throat, which may become intense or disruptive. It may assist with managing symptom intensity across conditions characterized by episodic or fluctuating manifestations, such as those associated with the common cold. The primary therapeutic focus is relevant for easing symptoms that include soreness, swelling, and difficulty swallowing.

Therapeutic Benefit

The therapy helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases. The therapy is applied in addressing symptom clusters that include inflammatory or irritative states and the resulting functional stress. This focus contributes to improved comfort during periods of heightened symptoms for both adults and adolescents. It is applied across therapeutic domains where short-term, supportive symptom management is appropriate, particularly when the discomfort is linked to acute inflammatory swelling.

---

Quick Fact: Strepfen is applied in scenarios where additional management of discomfort is required, helping to address symptom clusters that include soreness and swelling related to acute throat irritation.

---

The eligibility to use Strepfen (Flurbiprofen) is strictly defined by regulatory authorities based on age and pre-existing medical conditions, reflecting its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Regulatory Eligibility Scope

Eligibility Group	Regulatory Status
Approved Age Group	Adults and adolescents over 12 years of age.
Absolute Contraindications	Patients with known hypersensitivity to Flurbiprofen or other NSAIDs/Aspirin; active or history of recurrent peptic ulceration or GI bleeding; severe heart, renal, or hepatic failure.
Pregnancy Restrictions	Contraindicated in the third trimester of pregnancy. Not recommended during the first and second trimesters, or for women who are breastfeeding.

Condition-Based Restrictions

Regulatory documents require caution and close consideration for use in the elderly due to higher risk of serious adverse reactions. Caution is also mandatory for patients with a history of hypertension, non-severe heart failure, or mild to moderate impairment of renal or hepatic function. Use is not recommended for children under 12 years of age, as safety and efficacy have not been established in this younger population.

This framework ensures the product is limited to populations where its short-term use for local relief is deemed appropriate under official regulatory guidelines.

Interactions with Other Medicines and Products

Strepfen (Flurbiprofen) carries an interaction profile consistent with the Nonsteroidal Anti-inflammatory Drug (NSAID) class, requiring specific caution with several medicinal products and substances as documented in official regulatory labeling.

Official Regulatory Interaction Categories

Interaction Domain	Substances/Products with Documented Interaction
Pharmacodynamic Additive Risk	Other NSAIDs (including COX-2 inhibitors), Anticoagulants (e.g., Warfarin), Anti-platelet Agents, Corticosteroids (Oral)
Systemic Exposure Modification	Lithium, Methotrexate, Cardiac Glycosides
Renal Function Sensitivity	Antihypertensive Drugs (ACE inhibitors, ARBs), Ciclosporin, Tacrolimus

Specific Restrictions and Requirements

Official labeling specifies that co-administration with other NSAIDs or low-dose Acetylsalicylic acid (Aspirin) should be avoided due to an enhanced risk of gastrointestinal bleeding. A mandatory timing restriction requires that Flurbiprofen must not be used for 8 to 12 days after the administration of Mifepristone. Co-administration with Alcohol may increase the risk of adverse reactions, particularly gastrointestinal bleeding. Certain patient populations, such as CYP2C9 poor metabolizers and those with compromised renal function, have interaction notes related to reduced metabolic clearance and enhanced nephrotoxicity, respectively.

The mechanism of action for Flurbiprofen involves engaging specific molecular targets to modulate the body's inflammatory and pain signaling processes. The specialized delivery confines this action to a localized peripheral mechanism within the oropharyngeal tissues.

Targeting Cyclooxygenase Enzymes (COX)

This domain covers the primary molecular target: the Cyclooxygenase (COX) enzyme isoforms, specifically COX-1 and COX-2. Flurbiprofen functions as a non-selective competitive inhibitor of these enzymes, blocking the first step in the creation of crucial inflammatory mediators. This inhibition prevents the metabolism of Arachidonic Acid, modifying the chemical signals that drive the inflammation cascade.

Suppressing Prostaglandin-Mediated Signaling

The key pathway consequence of COX inhibition is the immediate and substantial reduction in the local biosynthesis of Prostaglandins, particularly Prostaglandin E2 ( PGE2). Suppression of these mediators results in two distinct physiological consequences: a reduction in the chemical signaling that heightens the sensitivity of peripheral nociceptors and a modulation of the local vascular responses that govern capillary permeability and exudation.

Localized Action and Mechanistic Constraint

Due to the specialized oromucosal delivery (lozenge/spray), the action is confined to a highly localized peripheral mechanism at the site of application. This constraint establishes a high concentration gradient of the molecule exactly where the COX enzymes are overactive, facilitating a prompt functional engagement of the mechanism and a timely translation into anti-inflammatory and pain-modulating physiological consequences in the oropharyngeal tissues.

How Strepfen is Used

Strepfen, which contains Flurbiprofen 8.75 mg, is administered according to a specific, short-term protocol. The administration principle is to utilize the lowest effective dose for the shortest time necessary to maintain the therapeutic window.

---

Official Administration Protocol

The product is approved for oromucosal administration, meaning it is applied directly to the lining of the mouth and throat to achieve a local effect.

Category	Administration Guidance
Route of Administration	Oromucosal only (Lozenge/Spray)
Standard Single Dose	One lozenge or one dose of the spray (8.75 mg)
Dosing Frequency	Administered as needed, with a minimum interval of 3 to 6 hours between doses
Maximum Daily Dose	5 lozenges or doses (43.75 mg) in a 24-hour period

---

Procedural and Time Constraints

The use of Strepfen is governed by precise procedural and duration limits. The lozenge is sucked slowly and consistently moved around the mouth during administration to minimize the risk of localized irritation. For the spray form, the device requires priming before initial use, and care is taken not to inhale the product during application.

Regarding the treatment duration, the therapy is limited to short-term use only, with a maximum treatment period of three days. The product is indicated for adults and adolescents over 12 years of age, though the spray formulation may have a minimum age of 18 years in some regions. No formal dose reduction is typically specified for patients with mild-to-moderate renal or hepatic impairment.

Research evidence / Overview of studies for Strepfen (Flurbiprofen)

---

Evidence for Use in Acute Sore Throat Symptoms

Randomized controlled trials (RCTs) and systematic reviews represent the primary body of research that was studied for Flurbiprofen oromucosal preparations (Strepfen). These short-term RCTs, which include placebo-controlled and double-blind setups, were used in research examining patient-reported outcomes describing perceived discomfort, focusing on outcomes related to physical discomfort in the throat. The trials specifically examined changes in the intensity of sore throat pain and the level of difficulty swallowing using validated patient scales.

The findings describe patterns observed in the studies where data show patterns related to symptom scores compared to inactive (placebo) controls. The research highlights changes measured during the study period; findings indicate that patterns of change were observed beginning within the first two hours after the product was administered. The evidence landscape, comprised of numerous RCTs and systematic reviews, has an evidence level categorized as High in coarse grading. However, the study designs focused on episodes where symptoms become more noticeable, and the results apply only to the populations studied.

---

Study of Symptom Onset and Duration of Effect

Research explored short-term symptom changes by specifically measuring the time to onset of relief and the typical duration of symptomatic change observed after a single dose. Research examined the timeline of patient-reported outcomes. Findings indicate that the measured change generally was monitored up to six hours after a single dose was administered. The follow-up durations were limited in these specific measurements, meaning there is limited information for long-term outcomes across multiple days of use.

---

Evidence in Specific Populations and Subgroups

The clinical research for Strepfen was evaluated in specific populations, primarily adults with moderate-to-severe symptoms. Research examined a limited scope of other populations, including adolescents (typically 12 years and older), whose data was observed in some studies for the lozenge formulation. Data for certain groups remain insufficient, such as patients with significant systemic diseases or other complex health conditions (comorbidities). Subgroup findings are uncertain when moving outside the primary population.

---

Long-Term Evidence and Follow-up Limitations

The clinical trials generally involved short-term follow-up periods, with the typical observation window for multiple-dose studies being between three and seven days. This research was conducted during periods of increased symptom activity. The research does not determine extended or maintenance use, and there is limited information for long-term outcomes or the consequences of using the product beyond the acute treatment window described in the studies. The follow-up durations were limited by the design of the trials themselves.

Key Studies & References

1. Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: a randomized, non-inferiority trial in the Russian Federation
2. A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events
3. Health Products Regulatory Authority PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE Scientific discussion Streps (Flurbiprofen 8.75 mg lozenge)
4. Public Assessment Report Scientific discussion Strepfen Orange Sugar free 8.75 mg, lozenges (flurbiprofen) NL/H/4697

How to Store and Dispose of Strepfen (Flurbiprofen)

Official regulatory labeling dictates strict conditions for the storage and final disposal of Strepfen (flurbiprofen 8.75 mg lozenges).

---

Storage Requirements

Condition Type	Requirement
Temperature	Do not store above 25 C; Do not refrigerate or freeze.
Packaging	Store in the original package to ensure protection from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired medicinal product and associated waste material must be disposed of in accordance with local requirements. The product must not be discarded via wastewater or standard household waste, as mandated by pharmaceutical waste regulations.